Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
  • Corporate reports
  • Facts, products, pipeline
  • Events calendar
  • Media contacts
  • Press releases
  • Photo library
  • Broadcast Centre
• Investors

You are here

• Home

• Media

Here you will find our corporate press releases, details on upcoming events and other useful information for business and financial media.

• Latest news collapse

  • 16 October 2009 SYMBICORT TURBUHALER Approved for the Treatment of Adult Asthma in Japan

    AstraZeneca today announced that Symbicort Turbuhaler (budesonide/formoterol) has been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) for the maintenance treatment of bronchial asthma in patients aged 16 and over when a combination therapy of an inhaled steroid and a long-acting beta-2 agonist is necessary.

  • 16 October 2009 US Food and Drug Administration Approves CRESTOR for Use in Pediatric Patients with Heterozygous Familial Hypercholesterolemia

    AstraZeneca today announced the US Food and Drug Administration (FDA) approved CRESTOR (rosuvastatin calcium) for use in children ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the “bad” cholesterol) and increased risk of early cardiovascular disease.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October
  2009.

  • View details of the event
  • View financial calendar

  Photo & video library collapse

  • Here you can download pictures from our photo library
  • Broadcast footage of AstraZeneca products and activities is available from our Broadcast Centre (requires registration)

• Key Facts collapse

  • We are a world leading pharmaceutical company with a world-class biologics capability.
  • We are active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US.
  • We employ over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia).
  • Alongside our commitment to competitiveness and performance, we continue to be led by our core values to achieve sustainable success.
  • More facts about AstraZeneca

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

Not signed in

Page tools

• Print
• Bookmark this page

Share price